Autores
Fernanda Cristina dos Santos Simão , Janaína Rosenburg Gioseffi , Nina Melo , Juliana Francisco , Fábio Fedozzi , João Vitor Damasceno Mourão , Catherine Moura
Instituições dos autores (EM ordem)
Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia , , Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia , Associação Brasileira de Linfoma e Leucemia
Resumo
INTRODUCTION: Breast cancer is the most common neoplasm among women and a serious public health issue. Treatment depends on the stage of the disease and the clinical conditions of the patient, such as age, menopausal status, among other factors. Inadequate management of health services can lead to waste and the absence of preventive procedures, resulting in high costs associated with hospitalizations and treatments. The aim was to identify the direct cost of first-line breast cancer treatment in the Sistema Único de Saúde (SUS). METHOD: A descriptive quantitative research was conducted on the cost of breast cancer treatment, focusing on the molecular subtypes triple-negative, HER2 positive, and hormone receptor-positive pre- and post-menopause. Different treatments were analyzed, including surgery, radiotherapy, chemotherapy, and hormone therapy, in a 55-year-old adult woman weighing 70 kg, at stages I, II, III, and IV of the disease. Financial data were collected in 2023 through SIGTAP (Procedure Table Management System of SUS) and the CMED Table (Medicine Market Regulation Chamber), ICMS of 17%. Values were presented in Brazilian currency (R$). RESULTS: The cost of first-line treatment for breast cancer patients varies according to the stage. At stage I, the expenses were: R$ 17,009.30 for HER-2 Negative HR+ pre-menopause, R$ 68,794.45 for post-menopause, R$ 125,321.27 for HER-2 Positive, and R$ 37,208.58 for Triple Negative. At stage II, costs were: R$ 29,257.58 for HR+ pre-menopause, R$ 97,660.27 for post-menopause, R$ 157,325.51 for HER-2 Positive, and R$ 37,981.42 for Triple Negative. At stage III, the values were: R$ 45,696.27 for HR+ pre-menopause, R$ 97,481.42 for post-menopause, R$ 165,580.55 for HER-2 Positive, and R$ 37,982.42 for Triple Negative. Finally, at stage IV, costs were: R$ 128,046.12 for HR+ pre-menopause, R$ 356,172.12 for post-menopause, R$ 237,569.19 for HER-2 Positive, and R$ 56,664.00 for Triple Negative. DISCUSSION AND CONCLUSION: The values reflect the variation in treatments and complexities according to the stage of breast cancer. The study emphasizes the importance of effective public policies for disease prevention and screening, as well as strategies to optimize SUS resources. Understanding the costs of first-line treatment is essential for health managers and policymakers, aiming to improve system efficiency. Early detection is crucial for better treatment outcomes and quality of life for patients.